Synergy Pharmaceuticals — Investor Presentation (January 2011)
33 slides from Synergy Pharmaceuticals's investor presentation, Jan 18, 2011
Slide 1: Developing new Treatments for GI Disorders and Diseases
Developing new Treatments for GI Disorders and Diseases January 10, 2011
Slide 2: Forward-Looking Information
Certain statements made in this presentation are forward-looking. Such statements are indicated by words such as “expect,” “should,” “anticipate” and similar words indicating uncertainty in facts and figures. Although Synergy believes that the expectations reflected in such forward-looking statement
Slide 3: Introduction to Synergy Pharmaceuticals Investment Highlights
Introduction to Synergy Pharmaceuticals Investment Highlights Proprietary Technology Targeted therapy – specific selective receptors in GI tract Proprietary (Guanylate Cyclase-C) GC-C Receptor Agonists Control 100% of worldwide commercial rights Lead Candidates Plecanatide to treat Chronic Constipat
Slide 4: GI Disorders & Diseases Significant Market Opportunity
GI Disorders & Diseases Significant Market Opportunity
Slide 5: IBS-C / CC – A Large and Growing Market
IBS-C / CC – A Large and Growing Market >100 million people worldwide suffer from IBS-C / CC High incidence of severe form 20 million in U.S., Europe & Japan High prevalence in the U.S. ~15% of U.S. population or ~45 million people suffer from CC and IBS-C 6.0 - 8.5 million patients in U.S. with CC
Slide 6: IBS-C / CC Competitive Landscape
IBS-C / CC Competitive Landscape Source: Sucampo & Takeda annual reports, Movetis annual report, Ladenburg Thalmann research report, press releases. Amitiza® Resolor® Linaclotide Only late-stage drug currently in development in U.S. Indication Stage Mechanism of Action (MOA) Most Common Side Effect(
Slide 7: GC-C Receptor Agonists
GC-C Receptor Agonists
Slide 8: Guanylate Cyclase C Receptor Agonists Physiological mechanism
Guanylate Cyclase C Receptor Agonists Physiological mechanism Cross section of the GI tract Activation of the GC-C receptors stimulates intracellular synthesis of cyclic GMP, resulting in activation of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) The CFTR, when activated, secretes
Slide 9: Plecanatide – A Superior Analogue of Uroguanylin
Plecanatide – A Superior Analogue of Uroguanylin 16-mer analogue of natural uroguanylin Single key amino acid change Locked into stable active conformer Compact stable molecule Thermo and acid stable (100 °C, pH 2) High resistance to proteases Behaves like a small molecule drug More potent than the
Slide 10: Plecanatide is a superior analog of the natural GI hormone uroguanylin
Uroguanylin Plecanatide Plecanatide is a superior analog of the natural GI hormone uroguanylin N D D C E L C V N V A C T G C L N D E C E L C V N V A C T G C L
Slide 11: Dominant IP against uroguanylin analogs
Dominant IP against uroguanylin analogs Key U.S. patent on plecanatide issued in 2006 Issued in Europe Allowed in Japan Synergy has pursued a strategy with narrow but strong claims Ironwood crafted their IP position primarily against ST-peptide analogs Pursued a broad strategy - filed thousands of p
Slide 12: Plecanatide Clinical Development
Plecanatide Clinical Development
Slide 13: Plecanatide Phase I Trial in Volunteers
Protocol No. SP-SP304101-08 Cohorts administered a single, oral dose of 0.1, 0.3, 0.9, 2.7, 5.4, 8.1,16.2, 24.3 and 48.6 mg Plecanatide or matching placebo 8 subjects per cohort 6 Plecanatide 2 Placebo 71 subjects total No systemic absorption of Plecanatide observed at any administered dose PK colle
Slide 14: Phase IIa Trial Design
A Phase IIa Randomized, Double-Blind, Placebo-Controlled, 14-Day Repeat, Oral, Dose-Ranging Study to Assess the Safety, Pharmacokinetic and Pharmacodynamic Effects of Plecanatide in Patients with Chronic Idiopathic Constipation (Protocol No. SP-SP304201-09) ROME III enrollment criteria Four dose coh
Slide 15: Phase IIa Safety Findings
Demographics: Primarily females (>80%) of Caucasian descent with mean age per cohort ranging from 47 to 51 years old (1) No detectable systemic absorption of Plecanatide Assay sensitivity >10 ng/mL No serious adverse events (SAE) reported in subjects receiving Plecanatide No deaths reported in this
Slide 16: Phase IIa Study Findings and Conclusions
Median Time to First Bowel Movement after Administration of First Daily Dose Change from Baseline in Spontaneous Bowel Movements (SBM) after 14-Days of Treatment (Per Protocol Population) Phase IIa Study Findings and Conclusions More than 50% of the population have 1st-bowel movement within 5 hours
Slide 17: Study Findings and Conclusions (cont'd)
Complete Spontaneous Bowel Movements (CSBM) pre-treatment and after 14-Days of Treatment (Per Protocol Population) Bristol Stool Form Score (BSFS) pre-treatment and after 14-Days of Treatment (Per Protocol Population) Study Findings and Conclusions (cont’d) 0.0 1.0 2.0 3.0 4.0 5.0 Placebo 0.3 mg 1.0
Slide 18: Phase IIa Study Findings and Conclusions (cont'd)
Change from Baseline in Bristol Stool Form Score (BSFS) after 14-Days of Treatment (Per Protocol Population) Phase IIa Study Findings and Conclusions (cont’d) Plecanatide Dose (mg) 0.0 0.5 1.0 1.5 2.0 2.5 Placebo 0.3mg 1.0mg 3.0mg 9.0mg Overall Tx Average Difference in BSFS Secondary endpoints such
Slide 19: Phase IIa Study Findings and Conclusions (cont'd)
% of Subjects Reporting Improvement in Abdominal Discomfort 0 20 40 60 80 Placebo 0.3 mg 1.0 mg 3.0 mg 9.0 mg Overall Tx % Subjects Reporting Improvement in Abdominal Discomfort Scores after 14-day Treatment Other key secondary endpoints including abdominal discomfort, constipation severity and over
Slide 20: Recent Developments
Recent Developments December 6th meeting with FDA led to option to considerably advance clinical development timescale for plecanatide: Strategy to perform next plecanatide trial as Phase II/III pivotal trial rather than conventional Phase IIb trial
Slide 21: Further Clinical Development of Plecanatide
Further Clinical Development of Plecanatide Next Step: Phase II/III 90-day Trial in CIC Patients
Slide 22: Phase II/III 90-Day Pivotal Study Design
A Phase II/III Randomized, Double-Blind, Placebo-Controlled, 90-Day Repeat Oral Dose-Ranging Pivotal Study to Assess the Safety and Efficacy of Plecanatide in Patients with Chronic Idiopathic Constipation Four treatment arms: Oral Plecanatide (0.5 mg, 1.0 mg, 3.0 mg) QD or matching placebo Approxima
Slide 23: Phase II/III Study Objectives
Phase II/III Study Objectives To evaluate the efficacy of once daily oral dosing of plecanatide (0.5 mg, 1.0 mg and 3.0 mg) as measured by the daily bowel movement diaries: Complete Spontaneous Bowel Movements (CSBM) – using responder analyses (> 3 CSBMs/wk with increase of > 1CSBM/wk ) (FDA mandate
Slide 24: Near-Term Milestones
2Q2011 Near-Term Milestones 3Q2011 3Q2012 2Q2012 3Q2012 4Q2012 1Q2011 2Q2011 1Q2012 2011 2012 Plecanatide Initiate Plecanatide Phase II/III 90-day CC pivotal trial Initiate Plecanatide Phase IIb 90-day IBS-C trial Plan to release Phase II/III 90-day CC top-line data Plan for End-of-Phase II/III meet
Slide 25: Synergy's GC-C Receptor Agonist Program is a Technology Platform
Synergy’s GC-C Receptor Agonist Program is a Technology Platform “2nd-generation” drug for Ulcerative Colitis (UC) GC-C agonists exhibit potent anti-inflammatory activity in animal models of inflammation TNBS Balb/c mice treated with GC-C agonists show histological improvement and suppressed intesti
Slide 26: Efficacy of GC-C Receptor Agonists in Animal Models of Ulcerative Colitis
Efficacy of GC-C agonists have been validated in three different acute animal models of ulcerative colitis - TNBS-induced colitis in Balb/c mouse - TNBS-induced colitis in BDF1 mouse - DSS-induced colitis in BDF1 mouse Preliminary data show that GC-C agonist treatment suppresses GI inflammation in a
Slide 27: SP-333 ameliorates DSS-induced GI inflammation in BDF1 mice
SP-333 ameliorates DSS-induced GI inflammation in BDF1 mice 0.0 1.0 2.0 3.0 Histopathology Colitis Score Control DSS DSS + Vehicle DSS + 5-ASA (100 mg/kg) 0.005 0.05 0.5 5.0 SP-333 (mg/kg)
Slide 28: GC-C agonists show histological improvement via suppression of cytokines
GC-C agonists show histological improvement via suppression of pro-inflammatory cytokines 0 40 80 120 IL-12 p40 IL-23 TNF Cytokines, pg/ml Control SP304, 50 ug/day 160 0 5 10 15 20 25 Histopathology Score SP-304 (ug/day) 0 10 20 50 n-9 n-8 n-4 n-5
Slide 29: Initial Clinical Trial Planned for SP-333
Initial Clinical Trial Planned for SP-333 Phase I single-dose, dose-escalation trial in healthy volunteers (N = 40) Safety, tolerability and PK of orally administered SP-333 Establish that SP-333 is not systemically absorbed in volunteers To be followed by evaluation in ulcerative colitis patients
Slide 30: Management Team
Gary S. Jacob, Ph.D.; President, CEO > 25 years of experience in the pharmaceutical and biotechnology industries G.D. Searle, Monsanto Co., Oxford University Primary focus: development of anti-inflammatory and antiviral drugs Alan F. Joslyn, Ph.D.; Member, Board of Directors; Chair, Clinical Oversit
Slide 31: Clinical Advisory Board
Clinical Advisory Board Douglas Drossman, M.D. Dr. Drossman is Professor of Medicine and Psychiatry (UNC School of Medicine, Division of Gastroenterology & Hepatology) and Co-Director of the UNC Center for Functional GI & Motility Disorders Michael Camilleri, M.D., Ph. D. Dr. Camilleri is Professor
Slide 32: Synergy: Opportunity Investment Highlights
Synergy: Opportunity Investment Highlights Proprietary Technology Targeted therapy – specific selective receptors in GI tract Proprietary (Guanylate Cyclase-C) GC-C Receptor Agonists Control 100% of worldwide commercial rights Lead Candidates Plecanatide to treat Chronic Constipation (CC – Phase II/
Slide 33: Financial Summary
Financial Summary Projected 2011 Cash Burn: $31.1 million Cash on hand (as of 10/22/2010): $3.3 million Fully Diluted Shares Outstanding as of October 19, 2010: 102,249,118
Synergy Pharmaceuticals — Investor Presentation (January 2011) on 6ix